JK 0564
Alternative Names: JK-0564Latest Information Update: 20 Aug 2025
At a glance
- Originator Tianjin Jikun Pharmaceutical Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours